Global Market for Viral Vector and Plasmid Manufacturing to Grow at a CAGR Of 16.28% during 2020-2030

 

A vector itself is a DNA molecule, consisting of an insert (transgene) and a larger sequence that serves as the pillar of the vector. The main role of the vector in transferring genetic information to another cell involves isolation, multiplication, or expression of the insert in the target cell. Viral and non-viral vectors are the two types of vectors.

Viral vectors are genetically engineered viruses that are used by molecular biologists as a carrier for the transmission of the genetic material to living organisms and in-vitro cell culture. Types of the viral vectors or choice of the virus depend upon several factors, including the size of the exogenous gene (transgene), stability and longevity of the transgene, the expression of the living cell, the types of the cell, transgene expression, and stability of the cell, among others. Adeno-associated virus, lentivirus, adenoviruses (Ads), retroviruses, poxviruses, baculoviruses, and herpes simplex viruses are some of the common types of viruses that are used as vectors.

Non-viral vectors mainly represent DNA plasmids that are delivered to the target cells as naked DNA or in association with different compounds, such as liposomes, gelatin, or polyamine nanospheres. Oligonucleotides and their analogs, cosmids, and artificial chromosomes can also act as non-viral vectors. The main advantages of these vectors over the viral ones are their simple large-scale production and low host immunogenicity.

According to the BIS Research, the global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030.  The global viral vector and plasmid manufacturing market is growing exponentially. However, growth is affected by several driving factors, as well as challenges. Despite having considerable challenges or restraints, the market is expected to progress at a low double-digit growth rate. Several future opportunities are expected to advance the market growth in the future.

Viral and non-viral vectors have emerged as well-organized delivery tools offering promising therapeutic approaches for previously intractable human diseases, including cancer, genetic, immunologic, neurodegenerative, ocular, as well as cardiovascular diseases, among others. Recent advancements made in vector-based gene and cell therapies, as well as in the field of vaccinology, have brought along a disruption in the healthcare sector globally. At present, both viral vectors and non-viral vectors, particularly plasmids, have been witnessing tremendous progress in innovative modifications and applications in both preclinical and clinical settings.

The global viral vector and plasmid manufacturing market is, therefore, perceived to be a market of high attractiveness by the investors. With a growing number of gene and cell therapy products in the pipeline and increasing approval of them, the market is expected to grow progressively. Furthermore, increased funding from private investors and the government for the development and expansion of vector manufacturing facilities is further expected to boost market growth.